University of Alberta biochemist discovers vital information on cancer-fighting gene

October 04, 2001

A University of Alberta biochemist has recreated the three-dimensional structure of a critical portion of the BRCA1 protein, which if mutated, causes hereditary breast cancer.

Using ultra-sensitive x-ray crystallography, Biochemistry assistant professor Mark Glover has uncovered the three dimensional structure of an important part of the breast cancer-associated protein, BRCA1. Mutations in BRCA1 cause about half of all hereditary breast cancers.

The structure may give clinicians the ability to formulate genetic screening programs to identify women at risk for the deadly disease. The finely detailed images, will give researchers new clues on how the crucial protein effectively prevents cells from becoming cancerous. It is a first step towards developing strategies to counteract the effects of the defective gene.

The protein is enormous in size and scope, with a chain of some 1,863 amino acids that comprises a complex, three-dimensional structure. Scientists have been focusing their investigations on the two ends of the protein, the C terminus and the N terminus. The focus of Dr. Glover's work has been the C-terminus, which consists of a pair of related structures, called BRCT repeats. BRCT repeats not only occur in BRCA1, but are a hallmark of a large family of proteins which play a role in the repair of DNA damage.

Researchers know that the ends of the complex protein are particularly susceptible to mutations implicated in breast and ovarian cancers. A team of researchers lead by University of Washington professor Rachel Klevit, using nuclear magnetic resonance imaging techniques, has been focusing its investigations on the N terminus.

Since the U of A work was published this month in Nature Structural Biology--the flagship journal for structural biologists--Dr. Glover has been fielding calls from clinicians around the world, who are interested in the implications the work may have for designing screening programs for breast cancer.

"They're very interested in our work," says Dr. Glover, who is now working much more closely with the clinicians. "This could help clinicians identify high-risk patients sooner and detect the disease much earlier."

Researchers at the University of Alberta have a particularly long and successful history of pioneering x-ray crystallography techniques. Mapping three-dimensional structures is crucial to researchers' understanding of the biological functions of proteins.
Dr. Glover's work was funded by the Canadian Institutes of Health Research, the Alberta Heritage Foundation for Medical Research and the Canadian Breast Cancer Research Initiative. Co-researchers include PhD student Scott Williams and technician Ruth Green.

Established in 1993, the Canadian Breast Cancer Research Initiative is Canada's primary agency for the funding of breast cancer research. CBCRI has contributed $71.7 million to support 249 research grants as of March 31, 2001. CBCRI partners include the Avon Flame Foundation, the Canadian Breast Cancer Foundation, the Canadian Breast Cancer Network, the Canadian Cancer Society, the Canadian Institutes of Health Research, Health Canada and the National Cancer Institute of Canada.

In 2001, an estimated 19,500 women in Canada will be diagnosed with breast cancer. An estimated 5,500 women will die from their disease.

The U of A in Edmonton, Alberta is one of Canada's premier teaching and research universities serving more than 30,000 students with 6,000 faculty and staff. It continues to lead the country with the most 3M Teaching Fellows, Canada's only national award recognizing teaching excellence.

University of Alberta

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to